Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes
Get Live Data
14,298.00    -20.00 (-0.14%)
Bid:
14,316.00
Ask:
14,318.00
Spread: 2.00 (0.014%)
Market Cap: £221.74b
AZN Live PriceLast checked at - London Stock Exchange

Intraday Astrazeneca Share Chart

Block listing Interim Review

3 Jun 2024 15:05

RNS Number : 6882Q
AstraZeneca PLC
03 June 2024
 

3 June 2024 15:05 BST

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

(Note: Italicised terms have the same meaning as given in the Listing Rules.)

 

Date: 3 June 2024

 

Name of applicant:

ASTRAZENECA PLC

Name of scheme:

ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME

Period of return:

From:

1 DECEMBER 2023

To:

31 MAY 2024

Balance of unallotted securities under scheme(s) from previous return:

4,420,134

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

330,091

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

4,090,043

 

Name of contact:

Hannah Tattersall

Telephone number of contact:

+44 (0)746 498 2582

 

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.

 

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

Adrian KempCompany Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRSDAFFFELSEFI
Date   Source Headline
8th Jan 20267:00 amRNSAZN new Head of Investor Relations Joris Silon
2nd Jan 20263:00 pmRNSTotal Voting Rights
22nd Dec 202511:00 amRNSDirector/PDMR Shareholding
22nd Dec 202511:00 amRNSDirector/PDMR Shareholding
22nd Dec 20257:30 amRNSEnhertu granted BTD for post-neoadjuvant early BC
22nd Dec 20257:30 amRNSEnhertu granted BTD for post-neoadjuvant early BC
22nd Dec 20257:00 amRNSUpdate on LATIFY Phase III trial of ceralasertib
22nd Dec 20257:00 amRNSUpdate on LATIFY Phase III trial of ceralasertib
19th Dec 202511:00 amRNSDirector/PDMR Shareholding
19th Dec 202511:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:05 amRNSSubcutaneous Saphnelo approved in EU
16th Dec 20257:00 amRNSEnhertu approved in US for 1L HER2+ metastatic BC
4th Dec 20253:00 pmRNSHolding(s) in Company
1st Dec 20253:05 pmRNSBlock listing Interim Review
1st Dec 20253:00 pmRNSTotal Voting Rights
26th Nov 20257:00 amRNSImfinzi approved in US for early gastric cancer
24th Nov 20257:00 amRNSAstraZeneca manufacturing investment in Maryland
20th Nov 20257:00 amRNSKoselugo (selumetinib) approved in the US
17th Nov 20253:00 pmRNSHolding(s) in Company
14th Nov 202511:00 amRNSDirector/PDMR Shareholding
10th Nov 20253:00 pmRNSDirector/PDMR Shareholding
6th Nov 20257:00 amRNS9M and Q3 2025 results
3rd Nov 20254:00 pmRNSResult of General Meeting
3rd Nov 20253:00 pmRNSTotal Voting Rights
28th Oct 20257:05 amRNSDirector Declaration
28th Oct 20257:00 amRNSKoselugo (selumetinib) approved in the EU
22nd Oct 20257:00 amRNSTezspire Approved in EU for CRSwNP
20th Oct 20257:05 amRNSUS FDA Approves Tezspire in CRSwNP
20th Oct 20257:00 amRNSPositive CHMP opinion for subcutaneous Saphnelo
13th Oct 20257:00 amRNSAgreement with US Govt to lower medicine prices
7th Oct 20257:00 amRNSBaxdrostat met primary endpoint in Bax24 Ph3 trial
6th Oct 20257:30 amRNSDatroway improved OS and PFS in TROPION-Breast02
1st Oct 20253:00 pmRNSTotal Voting Rights
29th Sep 20257:30 amRNSEnhertu improved IDFS in early BC in DB-05
29th Sep 20257:00 amRNSAZN harmonises listing structure
25th Sep 20254:30 pmRNSDirector/PDMR Shareholding
22nd Sep 20257:05 amRNSKoselugo recommended for EU approval
22nd Sep 20257:00 amRNSTezspire Recommended for Approval in EU for CRSwNP
17th Sep 20257:05 amRNSSaphnelo met primary endpoint in TULIP-SC
17th Sep 20257:00 amRNSUpdate on RESOLUTE Phase III trial
1st Sep 20253:00 pmRNSTotal Voting Rights
28th Aug 20253:00 pmRNSHolding(s) in Company
26th Aug 20253:00 pmRNSHolding(s) in Company
21st Aug 20253:00 pmRNSHolding(s) in Company
18th Aug 20253:00 pmRNSDirector/PDMR Shareholding
15th Aug 20253:00 pmRNSHolding(s) in Company
12th Aug 20253:00 pmRNSHolding(s) in Company
1st Aug 20253:00 pmRNSTotal Voting Rights
29th Jul 20257:00 amRNSH1 and Q2 2025 results
24th Jul 20257:00 amRNSGefurulimab nanobody met Phase III endpoints

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.